Expert Opinion on Biological Therapy最新文献_第3页

Clinical updates in mesenchymal stromal cell therapy for osteoarthritis treatment. 间充质间质细胞治疗骨关节炎的临床进展。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2025-01-01 Epub Date: 2024-12-25 DOI: 10.1080/14712598.2024.2446612

Gun-Il Im

{"title":"Clinical updates in mesenchymal stromal cell therapy for osteoarthritis treatment.","authors":"Gun-Il Im","doi":"10.1080/14712598.2024.2446612","DOIUrl":"10.1080/14712598.2024.2446612","url":null,"abstract":"Introduction: Osteoarthritis (OA) is a common chronic musculoskeletal disease with heterogeneous clinical manifestations and variable responses to different treatments. Unfortunately, there is no effective disease modifying therapy at present that can alter the natural course of the disease. Cell therapy based on mesenchymal stromal cells (MSCs) may offer an attractive therapeutic option for OA with their multiple modes of action, particularly immune-regulatory and regenerative capacities.Areas covered: In this narrative review, updates on mode of action based on patient's data, factors that can influence the efficacy of MSC treatment, current status in clinical application of MSCs as seen from randomized, controlled OA trials are introduced as well as the author's perspectives in the future of MSCs as OA therapeutics.Expert opinion: Symptomatic relief is not sufficient to justify the high cost associated with culture-expanded stem cells. Its advantages and efficacy over simple and low risk/cost modalities should be seriously reevaluated. Also, as the short-term strategy, efforts should be made to lower the cost of MSC therapy. In the future, multiomics technology may help to predict that subgroup of patients who will favorably respond to stem cell treatment, which would enhance the cost effectiveness and therapeutic benefit of MSC therapy.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"187-195"},"PeriodicalIF":3.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142876690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2025-01-01 Epub Date: 2025-01-13 DOI: 10.1080/14712598.2025.2453516

Ali Öksel, Hafize Emine Sönmez, Nihal Şahin

{"title":"Biosimilars in pediatric rheumatology: innovations, challenges, and opportunities.","authors":"Ali Öksel, Hafize Emine Sönmez, Nihal Şahin","doi":"10.1080/14712598.2025.2453516","DOIUrl":"10.1080/14712598.2025.2453516","url":null,"abstract":"Introduction: Biosimilars are biologic medications designed to closely replicate the properties of previously approved biologic disease-modifying anti-rheumatic drugs (bDMARDs). They offer a cost-effective alternative once the original product's patent has expired.Areas covered: In pediatric rheumatology, the use of biosimilars began in 2013 with the launch of the infliximab biosimilar. Since then, more biosimilars, including etanercept, rituximab, and adalimumab, have been introduced, providing additional treatment options for children with rheumatic diseases. This article explores the role of biosimilars in pediatric rheumatology, particularly in juvenile idiopathic arthritis, focusing on their development, safety, and efficacy, as well as the challenges associated with their clinical adoption. It also addresses the importance of education in improving understanding of biosimilars.Expert opinion: The article provides insights into their safety, effectiveness, and economic impact by reviewing current literature to help healthcare professionals make informed decisions for treating pediatric rheumatic diseases. Education for both patients and healthcare providers, effective communication, and expectation management play a critical role in ensuring appropriate treatment continuity.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"197-204"},"PeriodicalIF":3.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An evaluation of pozelimab for the treatment of CHAPLE disease. 评估波珠单抗治疗CHAPLE病的效果。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2025-01-01 Epub Date: 2024-12-12 DOI: 10.1080/14712598.2024.2438740

Salim Can, Melek Yorgun Altunbas, Ahmet Ozen

{"title":"An evaluation of pozelimab for the treatment of CHAPLE disease.","authors":"Salim Can, Melek Yorgun Altunbas, Ahmet Ozen","doi":"10.1080/14712598.2024.2438740","DOIUrl":"10.1080/14712598.2024.2438740","url":null,"abstract":"Introduction: CHAPLE disease is a severe, ultra-rare disorder caused by CD55 gene mutations, leading to uncontrolled complement hyperactivation, protein-losing enteropathy, and systemic thrombosis. Recent advances in targeted therapies, particularly the C5 inhibitor pozelimab (Veopoz), offer new treatment options by addressing complement dysregulation, marking a shift from symptomatic to precision therapy.Areas covered: This review explores the pathophysiology, clinical manifestations, and current treatments for CHAPLE disease. It examines pozelimab's pharmacological development, its mechanism as a C5 inhibitor, and results from Phase 1 to Phase 3 studies. Additionally, potential use of other anti-C5 therapies and emerging agents targeting proximal complement components are discussed. A systematic literature search using PubMed, Google Scholar, and ClinicalTrials.gov focused on studies from 2017 onwards to provide a comprehensive overview.Expert opinion: Managing CHAPLE disease requires a combination of targeted anti-complement therapies like pozelimab and supportive measures, including nutritional support and thrombosis management. While pozelimab shows promise in reversing core symptoms, risks like serious infections necessitate preventive measures, such as vaccination and antibiotic prophylaxis. Future research should focus on optimizing dosing, evaluating long-term safety, and assessing the need for lifelong therapy. Expanding our understanding of the disease's pathophysiology will refine treatment strategies and improve outcomes.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"1-7"},"PeriodicalIF":3.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142827770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An evaluation of sugemalimab for the treatment of relapsed or refractory extranodal natural killer T-cell lymphoma. sugemalimab治疗复发或难治性结外自然杀伤t细胞淋巴瘤的评价。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2025-01-01 Epub Date: 2024-12-22 DOI: 10.1080/14712598.2024.2444400

Yingfang Feng, Xia Liu, Jingwei Yu, Zheng Song, Lanfang Li, Lihua Qiu, Shiyong Zhou, Zhengzi Qian, Xianhuo Wang, Huilai Zhang

{"title":"An evaluation of sugemalimab for the treatment of relapsed or refractory extranodal natural killer T-cell lymphoma.","authors":"Yingfang Feng, Xia Liu, Jingwei Yu, Zheng Song, Lanfang Li, Lihua Qiu, Shiyong Zhou, Zhengzi Qian, Xianhuo Wang, Huilai Zhang","doi":"10.1080/14712598.2024.2444400","DOIUrl":"10.1080/14712598.2024.2444400","url":null,"abstract":"Introduction: Relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL) is a rare and aggressive subtype arising from natural killer or cytotoxic T-cells, predominantly affecting the nasal cavity and paranasal sinuses, lacking a standardized therapeutic approach. Sugemalimab, a fully human, full-length anti-PD-L1 immunoglobulin G4 (IgG4) monoclonal antibody (mAb), has been investigated in a Single-Arm, Multicenter, Phase II Study (GEMSTONE-201). The results demonstrated significant efficacy, favorable tolerability, and manageable adverse reactions of sugemalimab in R/R ENKTL. This study summarizes and compares the efficacy and safety profile of sugemalimab with several other PD-1/PD-L1 inhibitors in R/R ENKTL patients.Area covered: We included a Phase II study (GEMSTONE-201) of sugemalimab in R/R ENKTL.Expert opinion: The clinical trials have demonstrated superior efficacy of sugemalimab, evidenced by a complete response rate (CRR) of 35.9% and an overall response rate (ORR) of 44.9%. In comparison with other immune checkpoint inhibitors (ICIs), sugemalimab shows a notably higher CRR. Additionally, sugemalimab exhibits a manageable safety profile. Further evaluation of sugemalimab is required based on its efficacy and safety in real-world patient populations. Should sugemalimab be included in medical insurance in the future, it could potentially benefit a larger number of patients with R/R ENKTL.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"9-14"},"PeriodicalIF":3.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142863790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The potential of antibody-drug conjugates for effective therapy in diffuse large B-cell lymphoma. 抗体-药物偶联物在弥漫性大b细胞淋巴瘤有效治疗中的潜力。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2025-01-01 Epub Date: 2025-01-16 DOI: 10.1080/14712598.2025.2453524

Gulrayz Ahmed, Mehdi Hamadani, Taha Al-Juhaishi

{"title":"The potential of antibody-drug conjugates for effective therapy in diffuse large B-cell lymphoma.","authors":"Gulrayz Ahmed, Mehdi Hamadani, Taha Al-Juhaishi","doi":"10.1080/14712598.2025.2453524","DOIUrl":"10.1080/14712598.2025.2453524","url":null,"abstract":"Introduction: Antibody-drug conjugates (ADCs) are a rapidly evolving class of anti-cancer drugs with a significant impact on management of hematological malignancies including diffuse large B-cell lymphoma (DLBCL). ADCs combine a cytotoxic drug (a.k.a. payload) attached through a linker to a monoclonal antibody specific to a particular cancer antigen. Payloads include microtubule disruptors or DNA damaging chemicals. After attaching to the antigen, the ADCs are internalized, and the payload is dissociated from ADC by lysozymes and delivered to the intended site for exerting cytotoxic effects. This unique molecular design permits a better balance of efficacy and safety. Loncastuximab tesirine and polatuzumab vedotin are two ADCs approved in the U.S.A. for treatment of DLBCL.Areas covered: This review covers the efficacy and safety data of these two drugs. We will review new ADC-based combination regimens and novel constructs in development.Expert opinion: ADCs have made a significant impact in improving outcomes of DLBCL patients. Both polatuzumab vedotin and loncastuximab tesirine are established as useful therapeutics options, with polatuzumab vedotin currently approved in first line and relapsed/refractory setting, while loncastuximab tesirine is approved in relapsed setting. ADCs are effective with tolerable safety profile and currently many more ADCs are undergoing clinical trials.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"161-173"},"PeriodicalIF":3.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142964331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma. Idecabtagene微核（ide- cell）用于治疗三级暴露复发和难治性多发性骨髓瘤。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2025-01-01 Epub Date: 2024-12-09 DOI: 10.1080/14712598.2024.2433518

Katia Mancuso, Simona Barbato, Marco Talarico, Paola Tacchetti, Elena Zamagni, Michele Cavo

{"title":"Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma.","authors":"Katia Mancuso, Simona Barbato, Marco Talarico, Paola Tacchetti, Elena Zamagni, Michele Cavo","doi":"10.1080/14712598.2024.2433518","DOIUrl":"10.1080/14712598.2024.2433518","url":null,"abstract":"Introduction: Modern anti-myeloma therapies have broken new ground in the treatment of the disease, and the incorporation of ide-cel in the treatment landscape represents one of the major scientific and clinical advances.Areas covered: Ide-cel was the first cell-based gene therapy approved for the treatment of triple-class exposed relapsed/refractory myeloma patients, showing impressive results, and demonstrating superiority over standard regimens in terms of efficacy, potential treatment-free intervals, and improved quality of life in heavily pretreated patients and in high-risk disease. This review summarizes the state-of-the-art of the most recent updates deriving from the use of ide-cel within ongoing, or upcoming, clinical trials, and from real-life experiences.Expert opinion: As the use of chimeric antigen receptor (CAR)-T therapy is likely to progressively increase over time and current indications expand to earlier treatment lines, efforts should be directed toward ameliorating overall management to facilitate proactive planning for treatment sequencing and provide adequate time for logistical planning. Importantly, the potential limited availability of CAR-T therapy highlights the importance of careful patient selection and coordination among centers. Meanwhile, attempts are underway to improve tolerance and reduce toxicity while enhancing anti-myeloma activity.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"27-46"},"PeriodicalIF":3.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142800014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparing anti-drug antibody signal-to-noise ratios to assess immunogenicity and interchangeability in adalimumab biosimilar studies. 比较阿达木单抗生物仿制药研究中评估免疫原性和互换性的抗药抗体信噪比。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-12-01 Epub Date: 2024-11-19 DOI: 10.1080/14712598.2024.2428299

Lena Lemke, Andrew Blauvelt, Ines Brückmann, Hillel P Cohen, Jamie Fan, Davide Guerrieri, Matej Horvat, Johann Poetzl, Claudia Torella, Qingfeng Wang, Oliver von Richter

{"title":"Comparing anti-drug antibody signal-to-noise ratios to assess immunogenicity and interchangeability in adalimumab biosimilar studies.","authors":"Lena Lemke, Andrew Blauvelt, Ines Brückmann, Hillel P Cohen, Jamie Fan, Davide Guerrieri, Matej Horvat, Johann Poetzl, Claudia Torella, Qingfeng Wang, Oliver von Richter","doi":"10.1080/14712598.2024.2428299","DOIUrl":"10.1080/14712598.2024.2428299","url":null,"abstract":"Background: To support an interchangeability designation for Sandoz adalimumab biosimilar (GP2017), antidrug antibody (ADA) signal-to-noise (S/N) ratios were assessed in the GP2017 ADACCESS trial to directly assess potential changes in immunogenicity.Research design and methods: ADACCESS was a 51-week trial in patients with moderate-to-severe plaque psoriasis that included patients treated continuously with reference adalimumab (cH), and patients who experienced four switches between reference adalimumab and GP2017 (H2H). ADAs were measured every 6 weeks during the switching phase using an electrochemiluminescence assay. A non-parametric analysis was performed to estimate the 90% confidence interval (CI) of the median of difference in ADA S/N ratios between the cH and H2H treatment groups at week 41. If the 90% CI was within the margin of -0.16 to 0.16 (representing assay noise), this was considered a non-clinically meaningful difference in immunogenicity.Results: The 90% CIs of the median of difference in ADA S/N ratios between the two treatment groups were within the defined margin of -0.16 to 0.16 at week 41, and at all other time points. Efficacy and safety data were also similar between the treatment groups.Conclusion: Analysis of ADA S/N ratios showed no increase in immunogenicity following up to four switches between reference adalimumab and GP2017.Trial registration: NCT02016105.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"1375-1385"},"PeriodicalIF":3.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Endoscopic endpoints in biologic clinical trials and beyond: the case for Crohn's Disease. 生物临床试验中的内窥镜终点及其他：克罗恩病案例。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-12-01 Epub Date: 2024-11-18 DOI: 10.1080/14712598.2024.2430614

Marlou P M Adriaanse, Mark Löwenberg, Geert R A M D'Haens

{"title":"Endoscopic endpoints in biologic clinical trials and beyond: the case for Crohn's Disease.","authors":"Marlou P M Adriaanse, Mark Löwenberg, Geert R A M D'Haens","doi":"10.1080/14712598.2024.2430614","DOIUrl":"10.1080/14712598.2024.2430614","url":null,"abstract":"Introduction: Standardized evaluation of endoscopic disease activity using valid, responsive and reliable instruments is crucial for optimizing the efficiency of clinical trials with therapeutic agents for Crohn's disease (CD). Achieving endoscopic remission and/or mucosal healing is associated with improved long-term outcomes, making it an important treatment goal.Areas covered: Several endoscopic indices have been used over the past two decades, though they lack complete validation. The Crohn's Disease Endoscopic Index of Severity (CDEIS) and Simple Endoscopic Score for Crohn's Disease (SES-CD) demonstrate fair reliability and responsiveness to treatment. The CDEIS is rather complex and time-consuming, and both endoscopic indices are prone to variability. The Lewis Score and Capsule Endoscopy CD Activity Index (CECDAI) provide useful alternative instruments using video capsule endoscopy, but they need further validation. The Rutgeerts score predicts post-surgical recurrence but lacks evaluation for follow-up.Expert opinion: While recent guidelines emphasize co-primary clinical and endoscopic endpoints to improve trial effectiveness, these are typically based on expert consensus rather than empirical data. We advocate to use SES-CD as the preferred endoscopic index given its simplicity, strong correlation with CDEIS, and treatment responsiveness. Future research should focus on establishing clinically relevant cutoff values for endoscopic response and endoscopic remission in CD trials, including post-operative settings.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"1353-1362"},"PeriodicalIF":3.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging peptide-based technology for biofilm control. 基于肽的生物膜控制新兴技术。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-12-01 Epub Date: 2024-11-25 DOI: 10.1080/14712598.2024.2430623

Karen O Osiro, Nona Hashemi, José Brango-Vanegas, Samuel M D Oliveira, Octavio L Franco

引用次数: 0

Will zilebesiran, an RNA interference therapy, be effective, safe, and improve the treatment of hypertension? RNA干扰疗法齐来贝西兰是否有效、安全，并能改善高血压的治疗？

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-12-01 Epub Date: 2024-11-06 DOI: 10.1080/14712598.2024.2425343

Sheila A Doggrell

{"title":"Will zilebesiran, an RNA interference therapy, be effective, safe, and improve the treatment of hypertension?","authors":"Sheila A Doggrell","doi":"10.1080/14712598.2024.2425343","DOIUrl":"10.1080/14712598.2024.2425343","url":null,"abstract":"Introduction: Less than half of the subjects with hypertension have been diagnosed and treated, with only 21% having their blood pressure under control. Many of the subjects find it difficult to adhere to daily antihypertensives. Zilebesiran reduces hepatic angiotensinogen messenger RNA levels to inhibit the renin-angiotensin-aldosterone system and is being developed as a long-acting anti-hypertensive agent.Areas covered: KARDIA-1; a phase 2 clinical trial of zilebesiran with mild-to-moderate hypertension. Most doses of zilebesiran (150-600 mg) modestly reduced blood pressure from baseline to month 3. Adverse events included hyperkalemia and kidney failure.Expert opinion: The main problem with zilebesiran is that it only has a modest effect on blood pressure, and it is likely to have to be used as add-on therapy, which will probably reduce any benefits on adherence it has. It was also difficult to reliably interpret the results of KARDIA-1 as blood pressure went up significantly in the placebo group. KARDIA-1 did not answer previous concerns about zilebesiran; (i) what happens during volume depletion, sepsis, and pregnancy when angiotensinogen is inhibited long term or (ii) will it be effective in a high sodium diet.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"1329-1334"},"PeriodicalIF":3.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142568246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0